356 related articles for article (PubMed ID: 17545532)
1. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity.
Prado CM; Baracos VE; McCargar LJ; Mourtzakis M; Mulder KE; Reiman T; Butts CA; Scarfe AG; Sawyer MB
Clin Cancer Res; 2007 Jun; 13(11):3264-8. PubMed ID: 17545532
[TBL] [Abstract][Full Text] [Related]
2. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.
Ali R; Baracos VE; Sawyer MB; Bianchi L; Roberts S; Assenat E; Mollevi C; Senesse P
Cancer Med; 2016 Apr; 5(4):607-16. PubMed ID: 26814378
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
Saltz LB; Niedzwiecki D; Hollis D; Goldberg RM; Hantel A; Thomas JP; Fields AL; Mayer RJ
J Clin Oncol; 2007 Aug; 25(23):3456-61. PubMed ID: 17687149
[TBL] [Abstract][Full Text] [Related]
4. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.
Schwartz J; Toste B; Dizon DS
Gynecol Oncol; 2009 Jul; 114(1):53-6. PubMed ID: 19359030
[TBL] [Abstract][Full Text] [Related]
6. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
Schippinger W; Samonigg H; Schaberl-Moser R; Greil R; Thödtmann R; Tschmelitsch J; Jagoditsch M; Steger GG; Jakesz R; Herbst F; Hofbauer F; Rabl H; Wohlmuth P; Gnant M; Thaler J;
Br J Cancer; 2007 Oct; 97(8):1021-7. PubMed ID: 17895886
[TBL] [Abstract][Full Text] [Related]
8. Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin.
de la Torre A; García-Berrocal MI; Arias F; Mariño A; Valcárcel F; Magallón R; Regueiro CA; Romero J; Zapata I; de la Fuente C; Fernández-Lizarbe E; Vergara G; Belinchón B; Veiras M; Molerón R; Millán I
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):102-10. PubMed ID: 17869446
[TBL] [Abstract][Full Text] [Related]
9. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
[TBL] [Abstract][Full Text] [Related]
10. Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: a convenient treatment option in advanced gastric cancer.
Kundel Y; Purim O; Figer A; Stemmer SM; Tichler T; Sulkes J; Sulkes A; Brenner B
Med Sci Monit; 2008 Apr; 14(4):CR190-5. PubMed ID: 18376346
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
[TBL] [Abstract][Full Text] [Related]
12. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Siegel-Lakhai WS; Beijnen JH; Vervenne WL; Boot H; Keessen M; Versola M; Koch KM; Smith DA; Pandite L; Richel DJ; Schellens JH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4495-502. PubMed ID: 17671135
[TBL] [Abstract][Full Text] [Related]
13. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
[TBL] [Abstract][Full Text] [Related]
14. Measurement of total RBC volume relative to lean body mass for diagnosis of polycythemia.
Berlin NI; Lewis SM
Am J Clin Pathol; 2000 Dec; 114(6):922-6. PubMed ID: 11338481
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Amstutz U; Farese S; Aebi S; Largiadèr CR
J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
[TBL] [Abstract][Full Text] [Related]
16. Influence of birth size on body composition in early adulthood: the programming factors for growth and metabolism (PROGRAM)-study.
Leunissen RW; Stijnen T; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2009 Feb; 70(2):245-51. PubMed ID: 18616715
[TBL] [Abstract][Full Text] [Related]
17. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
[TBL] [Abstract][Full Text] [Related]
18. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
Kuebler JP; Colangelo L; O'Connell MJ; Smith RE; Yothers G; Begovic M; Robinson B; Seay TE; Wolmark N
Cancer; 2007 Nov; 110(9):1945-50. PubMed ID: 17853393
[TBL] [Abstract][Full Text] [Related]
19. [Results of hepatic arterial infusion chemotherapy with 5-FU and leucovorin for unresectable liver metastases from colorectal cancer].
Yamashita K; Urakami A; Kubota H; Nagatsuka R; Murakami H; Kawabe Y; Higashida M; Hirabayashi Y; Mikami Y; Ikeda M; Fuchimoto M; Yamamura M; Oka Y; Okumura H; Iki K; Matsumoto H; Imai S; Hirai T; Tsunoda T
Gan To Kagaku Ryoho; 2008 Jan; 35(1):71-6. PubMed ID: 18195531
[TBL] [Abstract][Full Text] [Related]
20. Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.
Beneton M; Chapet S; Blasco H; Giraudeau B; Boisdron-Celle M; Deporte-Fety R; Denis F; Narcisso B; Calais G; Le Guellec C
Br J Clin Pharmacol; 2007 Nov; 64(5):613-21. PubMed ID: 17578483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
